Journal of Endocrinological Investigation

, Volume 31, Issue 6, pp 505–508 | Cite as

Weight gain during the treatment of thyrotoxicosis using conventional thyrostatic treatment

  • M. S. Rathi
  • J. N. V. Miles
  • P. E. Jennings
Original Articles


Objective: Patients often lose considerable weight prior to the diagnosis of thyrotoxicosis. Regaining weight with treatment of thyrotoxicosis until hormone levels normalise is expected. This study was aimed to determine whether patients continued to put on weight once they were euthyroid. Study design and method: The records of 60 consecutive euthyroid patients were studied. All patients were rendered euthyroid on thyrostatic medication alone. Patients on a block and replacement regime, those who developed transient hypothyroidism on treatment or other diagnoses causing weight gain were excluded. Results: The mean age of study group was 46.13 yr (21–73). Male:female ratio was 5:55. 36 (60%) patients had diagnosis of Graves’ disease. On initial presentation weight was 67.75 kg (SEM 2.1) with body mass index (BMI) of 25.8. Patients took 6.7 months (mean) to become euthyroid. Mean weight when euthyroid was 71.61 kg (range 46–125). Even after becoming euthyroid, patient continued to gain weight at 3, 6, and 9 months and mean weight gain was 2.04 kg (SD 18.14) at 3 months (p=0.003). This weight gain was not related to patients’ age, gender, BMI, duration or dose of treatment required to achieve euthyroidism. Diagnosis of Graves’ disease and non-smoking status independently predicted weight gain. Conclusion: We have demonstrated that patients with thyrotoxicosis continue to gain weight for at least 6 months even after becoming euthyroid. Patients with Graves’ disease were more likely to gain weight compared to others. Smokers gained least weight. Preventing this weight gain warrants further investigation.


Thyrotoxicosis thyrostatic medication weight gain 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tunbridge WMG, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickam Survey. Clin Endocrinol (Oxf) 1977, 7: 481–93.CrossRefGoogle Scholar
  2. 2.
    Pears J, Jung RT, Gunn A. Long-term weight changes in treated hyperthyroid and hypothyroid patients. Scott Med J 1990, 35: 180–2.PubMedGoogle Scholar
  3. 3.
    Alton S, O’Malley BP. Dietary intake in thyrotoxicosis before and after adequate carbimazole therapy; the impact of dietary advice. Clin Endocrinol (Oxf) 1985, 23: 517–20.CrossRefGoogle Scholar
  4. 4.
    Hoogwerf BJ, Nuttall FQ. Long-term weight regulation in treated hyperthyroid and hypothyroid subjects. Am J Med 1984, 76: 963–70.PubMedCrossRefGoogle Scholar
  5. 5.
    Nystrom E, Stenlof K, Lonn L, et al. Changes in the Body Weight, Body Composition and Collagen related peptide after treatment for thyrotoxicosis, 68th Meeting, American Thyroid Association. Thyroid 1994, 4: S1–19 (abstract No 215).CrossRefGoogle Scholar
  6. 6.
    Dale J, Daykin J, Holder R, Sheppard MC, Franklyn JA. Weight gain following treatment of hyperthyroidism. Clin Endocrinol (Oxf) 2001, 55: 233–9.CrossRefGoogle Scholar
  7. 7.
    Abid M, Billington CJ, Nuttall FQ. Thyroid function and energy intake during weight gain following treatment of hyperthyroidism. J Am Coll Nutr 1999, 18: 189–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Lonn L, Stenlof K, Ottosson M, Lindroos AK, Nystrom E, Sojostrom L. Body weight and body composition changes after treatment of hyperthyroidism. J Clin Endocrinol Metab 1998, 83: 4269–73.PubMedGoogle Scholar
  9. 9.
    Larsen PR, Davies TF. Thyrotoxicosis. In: Larsen PR, Kronenberg HM, Melmed D, Polonsky KS, eds. Williams Textbook of Endocrinology, 10th ed, Philadelphia: Saunders 2002, 394.Google Scholar
  10. 10.
    Bayley TA, Harrison JE, McNeill KG, Mernagh JR. Effects of thyrotoxicosis and its treatment on bone mineral and muscle mass. J Clin Endocrinol Metab 1980, 50: 916–22.PubMedCrossRefGoogle Scholar
  11. 11.
    Zimmermann-Belsing T, Dreyer M, Holst JJ, Feldt-Rasmussen U. The relationship between the serum leptin concentrations of thyrotoxic patients during treatment and their total fat mass is different from that of normal subjects. Clin Endocrinol (Oxf) 1998, 49: 589–95.CrossRefGoogle Scholar
  12. 12.
    Morley JE. Neuropeptide regulation of appetite and weight. Endocr Rev 1987, 8: 256–87.PubMedCrossRefGoogle Scholar
  13. 13.
    Finer N, Sheikh S. Energy Expenditure, Intake and appetite in Graves’s disease before and after treatment. J Endocrinol 1996, 148 (suppl): 206.Google Scholar
  14. 14.
    Jo YH, Talmage DA, Role LW. Nicotine receptor-mediated effects on appetite and food intake. J Neurobiol 2002, 53: 618–32.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Grunberg NE. Nicotine as a psychoactive drug: appetite regulation. Psychopharmacol Bull 1986, 22: 875–81.PubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2008

Authors and Affiliations

  • M. S. Rathi
    • 1
  • J. N. V. Miles
    • 2
  • P. E. Jennings
    • 1
  1. 1.Centre for Diabetes and EndocrinologyYork HospitalYorkUK
  2. 2.Department of Health SciencesUniversity of YorkYorkUK

Personalised recommendations